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INTRODUCTION
Quantitative measurement of hepatitis B virus (HBV)
is valuable in predicting disease progression, monitoring
HBV replication activity and infectivity, and assessing the
response to antiviral treatment[1]. A number of commer-
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Background : Some differences exist among various Hepatitis B virus (HBV) DNA quantification
assays due to lack of standardization and besides clinical usefulness has not been firmly elucidat-
ed in Korean HBV patients.
Methods : We compared Bayer VERSANT HBV DNA 3.0 Assay (VERSANT 3.0) with Digene Hybrid
Capture II HBV DNA Test (HC-II) according to HBeAg status and ALT levels in 232 HBV-infected
Korean patients. One hundred and seventeen sera with undetectable DNA levels by HC-II were
further analyzed by Real-Q HBV quantification assay (BioSewoom). 
Results : Although VERSANT 3.0 and HC-II showed an excellent correlation (r=0.9739), the results
(copies/mL) by VERSANT 3.0 were 0.45 log10 higher than those by HC-II. HBV DNA levels were high-
er in HBeAg-positive group than in HBeAg-negative group (P=0.002), and in abnormal ALT group
than in normal ALT group (P<0.0001). The detection rate of HBV DNA by VERSANT 3.0 was lower
in HBeAg-negative and normal ALT group (n=68) than in HBeAg-positive or abnormal ALT group
(n=164) (35.3% vs 89.6%, P<0.0001). Fifty two sera out of 61 sera with undetectable DNA by VER-
SANT 3.0 were measurable by Real-Q with mean value of 3.26 log10 copies/mL.
Conclusions : VERSANT 3.0 and HC-II showed an excellent correlation, but a little difference (0.45
log10) existed. VERSANT 3.0 effectively measured clinically relevant HBV DNA levels in most HBV-
infected patients in Korea. However, more sensitive assays are needed for patients with negative
HBeAg and normal ALT to see the low copies of HBV DNA levels. (Korean J Lab Med 2007;27:451-7)
Key Words : Hepatitis B virus, DNA, Quantification, HBe antigen, Alanine aminotransferase
접 수 : 2007년 6월 30일 접수번호 : KJLM2048
수정본접수 : 2007년 8월 17일
게재승인일 : 2007년 8월 20일
교 신저 자 : 허 미 나
우 150-719 서울시 영등포구 영등포동 94-200
한림의대 한강성심병원 진단검사의학과
전화: 02-2639-5562, Fax: 02-2636-6764
E-mail: dearmina@hanmail.net
*This study was supported by Konkuk University Research Grant in
2005.
452 송은영∙허미나∙이규만 외 5인
cial assays are currently available for the quantification of
HBV DNA including hybridization-, signal-, and target-
amplification-based technologies. However, their results are
expressed with different units (e.g. mEq/mL, copies/mL,
WHO IU/mL) and some differences exist among them
due to lack of standardization[2, 3], which causes some
confusions to clinicians.
Hybrid Capture II test (HC-II, Digene Corp., Beltsville,
MD, USA) had better clinical sensitivity than the initial
version of branched DNA (bDNA) assay (VERSANT
1.0, Bayer HealthCare LLC, Tarrytown, NY, USA)[4]. A
new version of the bDNA assay, VERSANT HBV DNA
3.0 Assay (VERSANT 3.0), was recently developed with
better sensitivity than the previous version. Although these
assays are widely used in Korea, the difference between
them has been studied in only one study[5]. The main
purpose of our study was to compare the results of VER-
SANT 3.0 and HC-II to know the conversion factor be-
tween these two assays in Korean HBV-infected patients.
In addition, with the availability of new and potent
antiviral drugs, it becomes more important to measure
low levels of HBV DNA in order to predict the emer-
gence of drug-resistant HBV strains[6, 7]. VERSANT
3.0 was reported to have a wide dynamic range (2×103-
108 copies/mL) enough to cover clinically relevant HBV
levels[5]. To see the practical usefulness of VERSANT
3.0 in Korean HBV-infected patients and to investigate
how much the results of HBV DNA assays are affected
by the clinical status of patients, the results of VERSANT
3.0 were also analyzed according to HBeAg status and
alanine aminotransferase (ALT) levels, and those samples
with undetectable HBV DNA levels by HC-II were fur-
ther analyzed with another HBV DNA assay based on
real-time PCR, Real-Q HBV Quantification Assay (Real-
Q, BioSewoom Inc., Seoul, Korea).
MATERIALS AND METHODS
1. Patients
A total of 232 patients with chronic HBV infection
were consecutively recruited from the hepatitis clinic of
Hallym University Medical Center in January 2006. They
were 143 males and 89 females, and their median age
was 40 yr (range, 17-86 yr). They were all HBV sur-
face antigen (HBsAg) positive, and 133 patients (57.3%)
were HBV e antigen (HBeAg) positive and 99 patients
(42.7%) were HBeAg negative. HBV antigen tests were
performed at the time of recruitment using AxSYM ana-
lyzer (Abbott Laboratories, Abbott Park, IL, USA). Serum
ALT levels (normal range, <40 IU/L) were measured in
all patients using Neo-200FR autoanalyzer (Toshiba Med-
ical Systems Co., LTD., Tokyo, Japan).
One serum sample taken from each patient was used
for HBV DNA quantification by both VERSANT 3.0 and
HC-II. Samples with undetectable DNA levels by HC-II
were further analyzed by Real-Q (BioSewoom Inc.). In-
formed consent was obtained from each patient, and the
institutional review board approved the use of clinical
samples in this study.
2. HBV DNA quantification assays
1) VERSANT 3.0
VERSANT 3.0 was performed according to the man-
ufacturer’s instructions. The assay procedure consists of
two major activities, hybridization of the probes and mea-
surement of the light output, which occurs within a semi-
automated instrument, Bayer System 340 branched DNA
(bDNA) Analyzer. After denaturation, HBV genome was
hybridized to capture probes and target probes, which were
also hybridized to pre-amplifier probes. Amplifier probes
were subsequently hybridized to preamplifier probes, form-
ing a bDNA complex. This immobilized complex was then
hybridized to alkaline phosphatase (AP)-labeled probes,
and light emission was detected by incubating the AP-
bound complex with a chemiluminescent substrate. The
concentration of HBV DNA was determined by a stan-
dard curve, which was generated by six standards with
known concentrations of recombinant DNA. The results
were expressed in both copies/mL and the World Health
Organization (WHO) International Units (IU/mL). The
dynamic range of results was from 2.0×103 to 1.0×108
HBV DNA copies/mL. The relationship between both
values was 5.6 copies/mL=1 IU/mL for WHO reference
material NIBSC code 97/746 (5×105 IU/vial).
2) HC-II
HC-II is a nucleic acid hybridization antibody capture
microplate test with signal amplification utilizing chemi-
luminescent detection, and was performed according to
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the manufacturer’s instructions. After denaturation, HBV
DNA was hybridized to RNA probe mix (specific for
HBV ad and ay strains). The resultant RNA-DNA hybrid
was captured onto the surface of microwell coated with
antibodies specific for RNA-DNA hybrid, and this immo-
bilized hybrid was then reacted with AP-labeled anti-
bodies specific for it. The emitted light was measured on
a luminometer after an incubation of AP-bound hybrid
with a chemiluminescent substrate. The results were ex-
pressed in pg/mL according to the plot of standards, and
were converted to copies/mL (1 pg/mL=2.83×105 copies/
mL). The dynamic range of the results was from 0.5 to
6,000 pg/mL (from 1.42×105 to 1.70×109 copies/mL).
3) Real-Q
Real-Q is a real-time PCR method using TaqMan tech-
nology, which amplifies and quantifies a 112-bp region
of the HBV genome with a sensitivity of 50 copies/mL.
When Real-Q was evaluated by Clinical and Laboratory
Standards Institute guidelines[8, 9], the precision of total
coefficient of variation (CV) ranged from 1.29% to 1.88%
(for 6 log and 3 log levels, respectively), and the lineari-
ty from 1×102 to 1×1010 copies/mL. Briefly, 2 L of
internal control (IC) was added to 200 L of serum sam-
ples, and viral DNA was extracted using QIAamp MinE-
lute Virus Spin kit (QIAGEN Inc., Valencia, CA, USA).
Real-time PCR was undertaken with a final volume of
25 L (5 L of extracted DNA, 12.5 L of PCR mix-
ture, 3 L of HBV probe and primer mixture, 3 L of
IC probe and primer mixture and 1.5 L of sterile water)
using ABI PRISM 7000 system (Applied Biosystems, Fos-
ter City, CA, USA). After initial denaturation at 95℃ for
10 min, amplification was achieved by 45 cycles consisting
of 95℃ for 20 sec, 58℃ for 30 sec and 72℃ for 30 sec.
Five HBV standards calibrated against a commercial HBV
DNA control (ACCURUN 325 HBV DNA control: Bos-
ton Biomedica, Inc., West Bridgewater, MA, USA) were
used to generate a standard curve, by which quantifica-
tion data were calculated. Throughout the whole PCR
procedure, competitive homologous IC and uracil-N-gly-
cosylase were used to identify possible PCR inhibition and
to prevent possible carryover contamination, respectively.
3. Statistical analysis
Correlation and regression data were analyzed to define
the relationship between continuous variables. Bland and
Altman plot was used for the analysis of data agreement
[10]. The difference in log10 values for each matched pair
of results was plotted against the average of the log10
values for each pair. Horizontal lines were drawn at the
average difference, and at the average difference plus and
minus 1.96 times the standard deviation (SD) of the dif-
ferences. The differences of DNA levels between two
groups were analyzed by student’s t test. For the statis-
tical analysis, MedCalc software (version 9.20, MedCalc
software, Mariakerke, Belgium) was used. P≤0.05 was
considered statistically significant.
RESULTS
1. Comparison of VERSANT 3.0 with HC-II
Distribution of HBV DNA levels measured by VER-
SANT 3.0 and HC-II is summarized in Table 1. When
HBV DNA levels higher than or within the dynamic
range were combined together, they were detectable in
171 patients (73.7%) by VERSANT 3.0, and in 115 pa-
tients (49.6%) by HC-II. In all of these 115 patients, HBV
DNA was detected by VERSANT 3.0. The overall con-
cordance rate between these two assays was 75.9% (176/
232). All of the discordant results (24.1%, 56/232) were
positive by VERSANT 3.0 while negative by HC-II. 
Correlation and consistency of the difference between
VERSANT 3.0 and HC-II were analyzed in 54 patients
with HBV DNA levels within the dynamic ranges of both
assays (Fig. 1A). The scatter plot of the log10 quantita-
tive values by VERSANT 3.0 versus those by HC-II
showed a good linear relationship and a close data agree-
Abbreviations: HD, higher than detection limit; WD, within detection limit;
LD, lower than detection limit.
VERSANT 3.0 (copies/mL), N (%)
TotalHD 
(>108)
WD 
(2×103-108)
LD 
(<2×103)
HC-II (pg/mL)
HD (>6,000) 0 (0) 0 (0) 0 (0) 0 (0)
WD (0.5-6,000) 61 (26.3) 54 (23.3) 0 (0) 115 (49.6)
LD (<0.5) 0 (0) 56 (24.1) 61 (26.3) 117 (50.4)
Total 61 (26.3) 110 (47.4) 61 (26.3) 232 (100.0)
Table 1. Distribution of HBV DNA levels measured by VERSANT
3.0 and HC-II
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ment (r=0.9739, r2=0.9486, slope=0.8872). The formula
for interassay conversion between them was: HBV DNA
by VERSANT 3.0 (log10 copies/mL)=0.8872×HBV DNA
by HC-II (log10 copies/mL)+1.1666. In Bland-Altman plot
(Fig. 1B), the average difference between data pairs from
the two assays was 0.45 log10 (about 2.82 times higher)
with 95% confidence interval (CI) from 0.10 log10 to 0.81
log10, and it did not differ in both HBeAg-positive and
HBeAg-negative patients (0.48 log10 and 0.39 log10, res-
pectively). 
2. Performance of VERSANT 3.0 and HC-II according to
HBeAg status and ALT levels
The detection rates of HBV DNA by VERSANT 3.0
and HC-II were further analyzed in four groups accord-
ing to the HBeAg status and ALT levels (Fig. 2). The
detection rate of VERSANT 3.0 in patients with negative
HBeAg and normal ALT level (n=68) was significantly
lower than in patients with positive HBeAg or abnormal
ALT level (n=164) (35.3% vs 89.6%, P<0.0001). Such
a significant difference was mainly due to the differences
of HBV DNA levels in each group (Fig. 3). In 110 pa-
tients whose HBV DNA levels were within the dynamic
range of VERSANT 3.0, HBV DNA levels were signifi-
cantly higher in HBeAg-positive group (n=66) than in
HBeAg-negative group (n=44) (5.92 log10 vs 5.11 log10,
P=0.002) and in abnormal ALT group (n=48) than in
normal ALT group (n=62) (6.47 log10 vs 4.93 log10, P<
0.0001). There was also a moderate correlation between
HBV DNA levels and serum ALT levels in both HBeAg-
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Fig. 1. (A) Correlation of log10 quantitative HBV DNA levels between VERSANT 3.0 and HC-II. (B) Differences in log10 quantitative HBV DNA
levels between VERSANT 3.0 and HC-II in relation to average log10 quantification (n=54).
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Fig. 2. Detection rates of HBV DNA by VERSANT 3.0 and HC-II in
relation to clinical status of HBV. 
Abbreviations: HBeAg, hepatitis B virus e antigen; abnl, abnormal;
nl, normal.
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positive (r=0.4651, P=0.001) and HBeAg-negative groups
(r=0.4264, P=0.004).
3. Comparison of VERSANT 3.0 with Real-Q
In 117 patients with undetectable HBV DNA levels
by HC-II, Real-Q was further applied and their results
were compared with those by VERSANT 3.0. In 55 sera
with detectable HBV DNA levels by VERSANT 3.0,
HBV DNA were detected by Real-Q with the mean
value±2SD of 4.69 log10±0.68 log10 (Fig. 4). Out of 61
sera with undetectable HBV DNA levels by VERSANT
3.0, 52 sera showed detectable HBV DNA by Real-Q
with mean±2SD of 3.26 log10±0.51 log10, which was sig-
nificantly lower than in former 55 sera with detectable
DNA levels by VERSANT 3.0 (P<0.0001) (Fig. 4). The
correlation between VERSANT 3.0 and Real-Q in 55 sera
was also satisfactory (r=0.8329, r2=0.6937, P<0.0001)
(Fig. 5A). Check for between-method outliers for two
points which showed differences higher than mean+1.96
SD in Fig. 5 revealed that they were within the test limit
(four times average of absolute differences between two
methods), therefore could be used for comparison analy-
sis. In Bland-Altman plot, the average difference between
data pairs from these two assays was -0.23 log10 (95%
CI=-1.04-0.57 log10) (Fig. 5B).
DISCUSSION
A new version of bDNA assay, VERSANT 3.0, has
been recently introduced and showed a high specificity
(99.3%), an excellent reproducibility (between-run CV=
1.6-9.4%; within-run CV=6.5-20.7%), and a broad lin-
ear range of quantification (2.0×103-1.0×108 HBV DNA
copies/mL)[5]. However, there is a lack of standardiza-
tion among different HBV DNA quantification assays to
date. The previous version of VERSANT HBV DNA
assay usually showed definitely higher estimates than Hy-
brid Capture assays or PCR-based assays[11-14]. The new
VERSANT 3.0 has been also reported to show slightly
higher values than Hybrid Capture assays[5]. In our
study, the comparison between VERSANT 3.0 and HC-
II showed a good correlation coefficient (r2=0.9486). How-
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Fig. 4. Scatter plot shows HBV DNA levels measured by Real-Q
(log10 copies/mL) in sera with undetectable DNA by both of VER-
SANT 3.0 (V3.0) and HC-II (n=52) (left) and in sera with detectable
DNA by VERSANT 3.0 (V3.0) but undetectable by HC-II (n=55)
(right). Horizontal bars represent the means and±2SD. The dif-
ference between two groups was tested by Student’s t test. *P<
0.0001.
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Fig. 5. (A) Correlation of log10 quantitative HBV DNA levels between VERSANT 3.0 and Real-Q (n=55). (B) Differences in log10 quantitative
HBV DNA levels between VERSANT 3.0 and Real-Q in relation to average log10 quantification (n=55).
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ever, the average log10 difference between these two assays
was slightly higher with the value of 0.45 log10 (95% CI,
0.10-0.81) than the previous report (0.103 log10)[5].
The substantial difference may be due to different
detection principles and a lack of standardization. VER-
SANT 3.0 has standard materials calibrated against WHO
reference material 97/746, and the results are converted
to copies/mL (1 IU=5.6 copies/mL). HC-II has standard
materials (pg/mL), which are converted to copies/mL
using a conversion factor (1 pg/mL=2.83×105 copies/
mL), but not standardized with WHO standard HBV
DNA[3]. VERSANT 3.0 has been also reported to show
a relatively small average difference of 0.13 log10 compar-
ed with Cobas Taqman HBV test (Roche Diagnostics,
Meylan, France), which also uses internal quantification
standard (QS), and is standardized with WHO standard
HBV DNA[15]. Further studies and efforts for standard-
ization are still needed in this field. 
In our study, 52 out of 61 sera with undetectable HBV
DNA levels by VERSANT 3.0 were measurable by Real-
Q with a mean value of 3.26 log10 (about 1819.7) copies/
mL, most of them were below the lower detection limit
of VERSANT 3.0 (2×103 copies/mL). Therefore, from
a practical point of view, VERSANT 3.0 is satisfactory
because it has a lower detection limit (2×103 copies/mL)
enough to cover the clinically relevant HBV DNA levels,
considering that viral breakthrough is defined as an in-
crease of HBV DNA levels above 5 log10 copies/mL[16,
17] and more sensitive real-time PCR still could have
relatively higher CVs at very low HBV DNA levels accor-
ding to extraction methods or manufacturers[2, 18].
We tried to find an appropriate strategy regarding the
suitable HBV DNA quantification assay in routine clini-
cal settings in Korea, and analyzed the clinical sensitivity
of VERSANT 3.0 according to HBeAg status and ALT
levels. Our data shows that VERSANT 3.0 can be pri-
marily used for the patients with positive HBeAg or ab-
normal ALT levels (70.7%, 164/232 consecutive samples).
However, the low detection rate (35.3%) by VERSANT
3.0 in patients with negative HBeAg and normal ALT
levels (n=31) implies that a more sensitive assay is re-
quired to see the very low HBV DNA levels (below 2×
103 copies/mL) in these patients. 
In summary, the correlation between VERSANT 3.0
and HC-II was good across their overlapping dynamic
ranges, and the results (copies/mL) by VERSANT 3.0
were 2.82 times higher than those by HC-II. In routine
clinical settings, VERSANT 3.0 seems to be a satisfac-
tory choice for HBV DNA quantification in most of pa-
tients with positive HBeAg or abnormal ALT levels.
However, to see low HBV DNA levels in patients with
negative HBeAg and normal ALT levels, more sensitive
assays are needed. 
요 약
배경 : B형 간염 바이러스(hepatitis B virus, HBV) DNA
정량검사는 임상검사실에서 널리 이용되고 있으나, 서로 다른 검
사방법 간에 표준화가 되어 있지 않으며, 한국인 B형 간염 환자에
서 임상적 유용성에 대해 명확히 규명되지 않았다.
방법 : 232명의 한국인 B형 간염 환자를 대상으로 Bayer VE-
RSANT HBV DNA 3.0 Assay (VERSANT 3.0)를 Digene
Hybrid Capture II HBV DNA 검사(HC-II)와 비교하고 HBeAg
과 혈청 ALT 농도에 따라 평가하였다. HC-II로 검출한계 이하
인 117예를 Real-Q 정량 PCR (BioSewoom, Korea)로 추가 분
석하였다.
결과 : VERSANT 3.0과 HC-II는 우수한 상관관계를 보였으
나(r=0.9739), VERSANT 3.0의 결과(copies/mL)는 HC-II의
결과(copies/mL)에 비해 0.45 log10 높았다. HBV DNA 농도는
HBeAg 양성군에서 HBeAg 음성군에 비해 유의하게 높았으며
(P=0.002), 비정상 ALT군에서 정상 ALT군에 비해 유의하게
높았다(P<0.0001). VERSANT 3.0의 HBV DNA 검출률은
HBeAg 음성이고 정상 ALT군(n=68)에서 HBeAg 양성이고
비정상 ALT군(n=164)에 비해 유의하게 낮았다(35.3% vs 89.6
%, P<0.0001). VERSANT 3.0으로 HBV가 검출되지 않은 61예
중 52예는 Real-Q에서 검출 가능하였으며 평균 3.26 log10 copies/
mL의 값을 보였다.
결론 : VERSANT 3.0과 HC-II는 우수한 상관관계를 보였으
나, 결과 간에 약간의 차이(0.45 log10)가 존재하였다. VERSANT
3.0은 대부분의 한국인 B형 간염환자에서 임상적으로 유용하게
HBV DNA 정량이 가능하였다. 그러나, HBeAg 음성이고 정상
ALT를 보이는 환자들에서의 낮은 HBV DNA 농도를 정량하는
목적으로는 좀 더 예민한 검사가 필요할 것으로 생각된다.
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